Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma

Documenti analoghi

• Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
  di: Tetsu Tomonari, et al.
  Pubblicazione: (2024)
• Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
  di: Takeshi Hatanaka, et al.
  Pubblicazione: (2024)
• Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
  di: Margherita Rimini, et al.
  Pubblicazione: (2024)
• Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
  di: Toshifumi Tada, et al.
  Pubblicazione: (2024)
• Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
  di: Takahiro Kinami, et al.
  Pubblicazione: (2024)